{"url_path":"/sec/raph/10-q/2026/item-4","section_key":"item-4","section_title":"Item 4 Controls and Procedures**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1415397/0001213900-26-056181-index.html","accession_number":"0001213900-26-056181","cik":"0001415397","ticker":"RAPH","issuer_name":"Raphael Pharmaceutical Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1415397/0001213900-26-056181-index.html","primary_entity_key":"0001415397","primary_entity_name":"Raphael Pharmaceutical Inc."},"word_count":450,"has_tables":true,"body_markdown":"** **\n\n**Item 4. Controls and Procedures**\n\n** **\n\n**Management’s Conclusions Regarding Effectiveness\nof Disclosure Controls and Procedures**\n\n \n\nAs of March 31, 2026, we conducted\nan evaluation, under the supervision and participation of management including our Chief Executive Officer and Chief Financial Officer,\nof the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Securities Exchange\nAct of 1934, as amended). There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. Accordingly,\neven effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives.\n\n \n\nBased upon this evaluation,\nour Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective at the reasonable\nassurance level as of March 31, 2026.\n\n \n\n**Internal Control over Financial Reporting**\n\n \n\nThere were no changes in our\ninternal control over financial reporting during the fiscal quarter ended March 31, 2026, that materially affected, or are reasonably\nlikely to materially affect, our internal control over financial reporting.\n\n \n\nManagement is responsible\nfor establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under\nthe Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability\nof financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally\naccepted in the United States of America.\n\n \n\nBecause of inherent limitations,\ninternal control over financial reporting may not prevent or detect misstatements. Therefore, even internal controls determined to be\neffective can provide only reasonable assurance with respect to financial statement preparation and presentation. The effectiveness of\nour internal control over financial reporting is subject to various inherent limitations, including cost limitations, judgments used in\ndecision making, assumptions about the likelihood of future events, the possibility of human error, and the risk of fraud. The projection\nof any evaluation of effectiveness to future periods is subject to the risk that controls may become inadequate because of changes in\nconditions, or that the degree of compliance with policies may deteriorate. Because of these limitations, there can be no assurance that\nany system of internal control over financial reporting will be successful in preventing all errors or fraud or in making all material\ninformation known in a timely manner to the appropriate levels of management.\n\n \n\nThis Quarterly Report does\nnot include an attestation report of the company’s registered public accounting firm regarding internal control over financial reporting.\nManagement’s report was not subject to attestation by the company’s registered public accounting firm pursuant to rules of\nthe Commission that exempt from this requirement issuers that are neither accelerated filers nor large accelerated filers.\n\n \n\n10\n\n** **\n\n**PART II - OTHER INFORMATION**"}